Provided by Tiger Fintech (Singapore) Pte. Ltd.

Valneva SE

8.93
+0.41004.81%
Post-market: 9.110.1800+2.02%19:34 EDT
Volume:39.60K
Turnover:354.13K
Market Cap:759.89M
PE:-8.95
High:9.09
Open:8.70
Low:8.70
Close:8.52
52wk High:12.25
52wk Low:3.62
Shares:85.09M
Float Shares:64.58M
Volume Ratio:0.51
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9977
EPS(LYR):-0.1740
ROE:-38.01%
ROA:-6.58%
PB:3.48
PE(LYR):-51.31

Loading ...

A Lyme Disease Vaccine's Final Test Results Could Appear By Yearend. -- Barrons.com

Dow Jones
·
4 hours ago

Valneva Is Maintained at Buy by Guggenheim

Dow Jones
·
Sep 08

Valneva price target lowered to $13 from $14 at Guggenheim

TIPRANKS
·
Sep 08

Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July

Benzinga
·
Aug 26

Top Midday Decliners

MT Newswires Live
·
Aug 26

Valneva Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 26

Valneva Se : Jefferies Cuts Target Price to $14 From $18

THOMSON REUTERS
·
Aug 25

Valneva SE Down Over 21%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk

Dow Jones
·
Aug 25

Valneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.

Dow Jones
·
Aug 25

Valneva Se : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $18

THOMSON REUTERS
·
Aug 19

Valneva SE reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Stock Track | Valneva Shares Soar 9% on Strong H1 2025 Results and Positive Outlook

Stock Track
·
Aug 12

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 12

Stock Track | Valneva SE Surges 7.53% Pre-market on Strong H1 2025 Results and Positive Outlook

Stock Track
·
Aug 12

Valneva Shares Gain After Results, Outlook

Dow Jones
·
Aug 12

Valneva H1 Revenue €97.6M Up From €70.8M YoY, Net Loss €20.8M Down From Net Profit €34M YoY

Benzinga
·
Aug 12

Press Release: Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 12

Valneva SE expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Aug 08

Valneva Signs Deal With AGC Biologics for Phase 2 Trials of Shigella Vaccine Candidate

MT Newswires Live
·
Jul 29

Europe's Medicines Agency Lifts Temporary Age Restriction on Valneva's Chikungunya Vaccine

MT Newswires Live
·
Jul 11